Plus   Neg

Stock Alert: Renalytix Gains 17% On Winning Multi-year Contract

Renalytix AI plc (RNLX) shares are rising on Thursday morning trade as the company got a 10-year contract from the U.S. General Services Administration to provide KidneyIntelX early-stage kidney disease bio-prognostic testing services.

Currently, shares are at $29.64, up 17.53 percent from the previous close of $25.22 on average volume of 807,302. The shares have traded in a range of $9.91-$32.12 on average volume of 121,351 for the last 52 weeks.

The company noted that when the GSA contract will help KidneyIntelX testing to be available through the Federal Supply Schedule.

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Pharma Stocks by Subscribing to RTT Biotech Investor.
Follow RTT